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Objective: Previous studies suggest that low vitamin D status is associated with obesity charac-
terized by excess lipid storage in adipocytes. The aim of the present study was to determine the
effects of the most hormonally active form of vitamin D 1,25-dihydroxyvitamin D [1,25(OH)2D] on
adipocyte fat storage and lipid metabolism in mature 3T3-L1 cells.
Methods: Differentiated 3T3-L1 cells were treated with various concentrations of 1,25(OH)2D.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell proliferation, intracellular lipid
content, and basal and isoproterenol-stimulated lipolysis were measured to investigate the regu-
latory role of 1,25(OH)2D in adipocyte lipid metabolism. Reverse transcription polymerase chain
reaction was performed to determine the effects of 1,25(OH)2D on adipogenesis-related markers,
fatty acid oxidation-associated genes, and lipolytic enzymes. Sirtulin 1 (SIRT1) activity, nicotin-
amide adenine dinucleotide (NAD) and NADH were measured.
Results: 1,25(OH)2D treatment (24 h, 100 nmol/L) induced a decrease in intracellular fat accumu-
lation and an increase of basal and isoproterenol-stimulated lipolysis without cell toxicity in adi-
pocytes. Adipogenic gene levels were decreased. In contrast, mRNA levels of b-oxidation–related
genes, lipolytic enzymes, and vitamin D responsive gene were elevated by 1,25(OH)2D. Addi-
tionally, signiﬁcant incremental changes in NAD levels, the ratio of NAD to NADH, and SIRT1
expression and activity were noted in 1,25(OH)2D-treated 3T3-L1 adipocytes.
Conclusions: The observed potent inhibitory effect of 1,25(OH)2D on adipocyte fat storage in
mature 3T3-L1 cells suggests that vitamin D might improve adipocyte metabolic function and
protect against obesity. Increased NAD concentrations and SIRT1 activity may play a role in the
mechanism of 1,25(OH)2D action.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Obesity is recognized as amajor risk factor for type 2 diabetes,
dyslipidemia, hypertension, and heart disease [1,2]. It is charac-
terized by a signiﬁcant increase of adiposity, depending on
hypertrophy of preexisting individual adipocytes and/or hyper-
plasia due to the formation of new adipocytes from precursor
cells (adipogenesis) [3,4]. Additionally, the synthesis and release
of adipocyte-derived factors regulating insulin sensitivity areesearch Program through
nded by the Ministry of
) and Brain Korea 21 Plus
r Inc. This is an open access artialtered, which, in turn, leads to systemic insulin resistance and
type 2 diabetes [5]. Thus, an understanding of the molecular
mechanisms of adipose tissue formation and alterations during
the progression of obesity is required for the prevention and
treatment of obesity.
Accumulating evidence shows that vitamin D deﬁciency
is highly prevalent in obese people, indicating obesity might
be an independent risk factor for vitamin D deﬁciency [6,7].
Indeed, body fat content is negatively correlated with
25-hydroxyvitamin D [25(OH)D] concentrations, a commonly
accepted marker for vitamin D status [8–10]. In contrast, weight
loss leads to a signiﬁcant increase of 25(OH)D in obese children
and adults [11,12]. Following human epidemiologic and clinical
studies, numerous studies using in vitro adipocytes have
demonstrated the regulation of 1,25-dihydroxyvitamin D [1,cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
E. Chang, Y. Kim / Nutrition 32 (2016) 702–708 70325(OH)2D, calcitriol], the most active form of vitamin D, in
adipocyte differentiation. In cultured 3T3-L1 adipocytes, 1,
25(OH)2D treatment signiﬁcantly inhibits adipogenesis [13–15]
and decreases fat content by increasing the expression and
activity of lipolysis by lipoprotein lipase (LPL), which is involved
in adipocyte fat uptake and storage [16]. However, 1,25(OH)
2D–reduced adipogenesis is not observed in primary mouse or
human preadipocytes [17]. Given the high prevalence of vitamin
D deﬁciency in obese individuals and the strong association
between vitamin D and body fat mass, a better understanding of
vitamin D action and regulation in adipocyte physiology and
pathophysiology is critical for the prevention of obesity and its
associated health problems. However, the mechanisms by which
1,25(OH)2D inﬂuences adipocyte differentiation, lipid meta-
bolism, and the energy balance are largely unknown.
Sirtulin 1 (SIRT1), the mammalian homolog of yeast silent
information regulator 2, is a nicotinamide adenine dinucleotide
(NAD)-dependent protein deacetylase and an importantmetabolic
sensor in response to cellular energy status [18–20]. Fasting or
caloric restriction induces an increase of intracellular NAD, which
in turn stimulates SIRT1 activity, leading to hepatic glucose pro-
duction and an increase of oxidative machinery activity [18,21,22].
SIRT1 promotes fat mobilization from adipose tissue to support
lipid oxidation and inﬂammation [23]. Additionally, the genetic
deletion of SIRT1 in adipose tissue induces an increase in adipocyte
mass, inﬂammation, and metabolic disorders [24,25]. Thus, tar-
geting SIRT1 activation has been proposed as a therapeutic tool for
obesity and its associated metabolic dysfunction [26].
In the present study, we investigated the mechanisms by
which active vitamin D affects adipocyte fat storage, lipolysis,
and SIRT1 levels in 3T3-L1 cells. We hypothesized that 1,25(OH)
2D treatment inhibits intracellular fat accumulation and
enhances the NAD-to-NADH ratio and SIRT1 activity, accompa-
nied by changes in gene expression related to adipogenesis, fatty
acid oxidation, and lipolytic enzymes in 3T3-L1 adipocytes.
Materials and methods
Cell culture
Murine 3T3-L1 cells obtained from the American Type Culture Collection
(ATCC CL-173; Manassas, VA, USA) were maintained in high glucose (HG)-DMEM
(Gibco, Grand Island, NY, USA) containing 10% bovine calf serum (Gibco), 100 U/
mL of penicillin, and 100 mg/mL of streptomycin (Gibco) at 37C in 95% air and 5%Table 1
Primers used for real-time polymerase chain reaction
Gene GeneBank no. Forward sequence
ACO NM_015729.3 ATC CAG ACT TCC AAC ATG AG
aP2 NM_024406.2 CGA CAG GAA GGT GAA GAG C
b-actin NM_007393.3 GGA CCT GAC AGA CTA CCT CA
CEBPa NM_001287523.1 ATA GAC ATC AGC GCC TAC AT
CPT1a NM_013495.2 GTG TTG GAG GTG ACA GAC TT
CYP24 NM_009996 AGT GAA CCT GTG GAG ATG CT
FAS NM_007988.3 AAC TCA CTG GCA GAA GAG AA
HSL NM_010719.5 TAT GGA GTG AGG GTG CCA GA
Leptin NM_008493.3 TTC CTG TGG CTT TGG TCC TA
LPL NM_008509.2 ACT TGT CAT CTC ATT CCT GG
PGC1a NM_008904.2 GGG CCA AAC AGA GAG AGA G
PPARa NM_011144.6 ATC CCA TCA CTC TCT CTG TG
PPARg NM_001127330.1 TTG ATT TCT CCA GCA TTT CT
SCD-1 NM_009127.4 ATG GAT ATC GCC CCT ACG AC
SIRT1 NM_019812.2 TAC CCC ATG AAG TGC CTC AA
UCP1 NM_009463.3 CAG GCT TCC AGT ACC ATT AG
ACO, acetyl-CoA oxidase; aP2, fatty acid-binding protein 2; CEBPa, CCAAT/enhanc
dihydroxyvitamin D3 24-hydroxylase; FAS, fatty acid synthase; HSL, hormone-sensit
ceptor gamma coactivator 1a; PPAR, peroxisome proliferator-activated receptor; SCD-
factor A; UCP1, uncoupling protein 1carbon dioxide. After the preadipocytes reached conﬂuence (day 0), ﬁbroblasts
were incubated with 10% fetal bovine serum (FBS)-containing HG-DMEM in the
presence of 0.5 mmol/L of 3-isobutyl-1-methylxanthine (Sigma, St. Louis, MO,
USA), 1 mmol/L of dexamethasone (Sigma), and 5 mg/mL of bovine insulin (Sigma)
for 2 d to induce differentiation (day 2), followed by incubation with insulin for
an additional 2 d (day 4). The mediumwas replaced with DMEM containing 10%
FBS every 2 d until >95% of the cells contained lipid droplets (day 6 or 7). Mature
adipocytes were treated with vehicle control (0.1% ethanol) or 1,25(OH)2D
(Sigma) dissolved in absolute ethanol at the given concentrations for the indi-
cated time period.
MTT assay
Differentiated 3T3-L1 adipocytes were treated with different concentrations
of 1,25(OH)2D in 10% FBS-containing medium for 24 or 48 h. To determine the
relative viable levels, further incubation with fresh medium containing 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5 mg/
mL) was executed for 1 h. After dissolving in DMSO, the absorbance was
measured by a Varioskan plate reader (Thermo Electron, Waltham, MA, USA) at a
wavelength of 595 nm. The results are expressed as the fold-change compared
with the vehicle-treated cells.
Oil Red O staining
The intracellular lipid contents in differentiated adipocytes were measured
by Oil Red O (ORO) staining. Brieﬂy, the cells were washed with phosphate-
buffered saline (PBS), ﬁxed with 10% formaldehyde in PBS for 1 h, washed with
distilled water, and completely dried. The cells were subsequently stained with
ORO for 1 h at room temperature, washed with distilled water, and air-dried.
ORO-stained adipocytes were observed under a microscope (Olympus, Tokyo,
Japan) and digital images were captured at 40magniﬁcation. For a quantitative
analysis of intracellular lipid accumulation, ORO-stained lipids were eluted by
adding 100% isopropanol and measured at a wavelength of 490 nm.
Lipolysis
The adipocytes were washed with PBS and incubated in the absence or
presence of 10 mmol/L b-adrenergic agonist isoproterenol in 2% fatty acid free
bovine serum albumin containing medium. Basal and isoproterenol-stimulated
lipolysis was assessed by the release of glycerol in the culture medium using a
free glycerol reagent (Sigma) as previously described [27].
RNA analysis
Total RNAwas puriﬁed using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA)
according to manufacturer’s instruction. Reverse transcription (RT) of the total
RNAwas performed using MMLV reverse transcriptase (Bioneer, Daejeon, Korea)
and the reaction was performed at 37C for 60 min followed by incubation at
95C for 5 min. The primers used for RT-polymerase chain reaction (PRC) are
presented in Table 1. Real-time quantitative PCR was performed using the
AccuPower 2 Greenstar qPCR Master Mix (Bioneer) and a ﬂuorometric thermalReverse sequence Product size (bp)
AAC CAC ATG ATT TCT TCA GG 136
A ATT CCA CCA CCA GCT TGT CA 128
GTT GCC AAT AGT GAT GAC CT 208
TCC CGG GTA GTC AAA GTC AC 147
CAC TTT CTC TTT CCA CAA GG 100
G AGT TGT CCC ATG CTC TGG TC 200
CTT CAA GAA GAT AGC CAT GC 134
ATG GTC CTC TGC CTC TGT CC 173
ACC GAC TGC GTG TGT GAA AT 127
TCT CAT ACA TTC CCG TTA CC 112
G GTT TCG TTC GAC CTG CGT AA 266
AAC TAC CTG CTC AGG ACT CA 191
TGT TGT AAG GCT GGG TCT TT 171
GAT GTG CCA GCG GTA CTC AC 147
AAC CAA TTC CTT TTG TGG GC 215
CTT GGA CTG AGT CGT AGA GG 160
er binding protein a; CPT1a, carnitine palmitoyltransferase 1a; CYP24, 1,25-
ive lipase; LPL, lipoprotein lipase; PGC1a, peroxisome proliferative-activated re-
1, stearoyl-CoA desaturase 1; SIRT1, sirtuin 1; Tfam, mitochondrial transcription
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data were analyzed using the comparative Ct (DDCT) method for relative quan-
tiﬁcation [28]. Each target gene was normalized to that of b-actin and expressed
as a fold-change compared with controls.
SIRT1 activity assay
SIRT1 activity was measured using a SIRT1 activity assay kit (Abcam, Cam-
bridge, MA, USA) according to the manufacturer’s instructions. In brief, nuclear
fraction from differentiated 3T3-L1 adipocytes was extracted and puriﬁed. Next,
SIRT1 activity was measured in the presence of NAD and ﬂuoro-substrate pep-
tides using a ﬂuorometric microplate reader at 340 nm/460 nm wavelengths.
Measurement of the NAD-to-NADH ratio
A NAD/NADH assay kit was used to evaluate the levels of NAD, NADH, and
their ratio (Abcam). Differentiated adipocytes were snapped and frozen in liquid
nitrogen and extracted on ice with extraction buffer from the NAD/NADH assay
kit. Protein concentration was determined using a BCA protein assay kit (Pierce,
Rockford, IL, USA). The NAD and NADH values were normalized to their respec-
tive protein concentrations.
Statistical analysis
The data are presented as the mean  SEM of at least two independent
triplicate experiments. Statistical analysis was performed using PASW Statistics
21 (SPSS Inc., Chicago, IL, USA). Differences were determined using Student’s t
test. Statistical signiﬁcance was deﬁned as P < 0.05.
Results
1,25(OH)2D treatment (24 h) did not alter cell viability in mature
3T3-L1 adipocytes
The affect of 1,25(OH)2D on cell toxicity was examined by the
MTTcell proliferation assay following treatment of differentiated
adipocytes with vehicle or 1,25(OH)2D treatment. As shown in
Figure 1A, 24-h incubation with 1,25(OH)2D up to 100 nmol/L
had no effect on cell viability. In contrast, 48-h incubation with
1,25(OH)2D induced a signiﬁcant reduction, starting at a dose of
1 nmol/L. Thus, the dose of 100 nmol/L 1,25(OH)2D and 24 h
incubation was chosen for further experiments.
1,25(OH)2D signiﬁcantly decreases lipid accumulation in a dose-
dependent manner
Next, we investigated the effect of 1,25(OH)2D on adipo-
genesis. Differentiated 3T3-L1 adipocytes were incubated with
1,25(OH)2D for 24 h in a dose-dependent manner on day 6 or 7
after adipocyte differentiation induction. Representative imagesFig. 1. The effect of 1,25(OH)2D on cell viability in differentiated 3T3-L1 adipocytes. On da
100 nmol/L of 1,25(OH)2D for 24 h (A) or 48 h (B). The value of each bar represents the meof Oil Red O staining illustrate that 1,25(OH)2D inhibits lipid
accumulation (Fig. 2B). As Figure 2A shows, 24 h of 1,25(OH)2D
treatment inhibited adipogenesis in a dose-dependent manner
with a 15% signiﬁcant reduction evident at 100 nmol/L 1,25(OH)
2D as measured by Oil Red O staining.
1,25(OH)2D promotes basal and isoproterenol-stimulated lipid
utilization in 3T3-L1 adipocytes
To demonstrate whether the 1,25(OH)2D-decreased intra-
cellular fat content is due to lipolysis, we measured glycerol
levels in the culture medium after 24 h treatment. Figure 3
demonstrates that there were signiﬁcant reduction of the basal
lipolysis rates in 1,25(OH)2D-treated 3T3-L1 adipocytes. We next
sought to determinewhether 1,25(OH)2D leads to lipolysis in the
isoproterenol-stimulated state. Incubation of 3T3-L1 adipocytes
with a b-adrenergic agonist (isoproterenol, 10 mmol/L) on day 7
induced a signiﬁcant increase of 51% compared with the control
in the basal state. 1,25(OH)2D-treated adipocytes stimulated
with isoproterenol signiﬁcantly promoted lipid mobilization.
Thus, 1,25(OH)2D might increase fatty acid availability due to
enhanced basal and isoproterenol-stimulated lipolysis from
adipocyte lipid accumulation.
Effects of 1,25(OH)2D on gene expression involved in
adipogenesis, fatty acid oxidation, lipolytic enzymes, vitamin D
metabolism, and obesity-associated adipocytokine
We evaluated whether 1,25(OH)2D diminished lipid accu-
mulation by regulating the gene involved in adipogenesis, fatty
acid oxidation, and adipocyte-speciﬁc lipolytic enzymes.
1,25(OH)2D (24 h, 100 nmol/L) signiﬁcantly decreased aP2,
CEBPa, FAS, PPARg, and SCD-1 adipogenic mRNA expression by
43.9%, 63.4%, 60.2%, 49.2%, and 62%, respectively (Fig. 4A).
Additionally, mRNA levels of CPT1a, PGC1a, PPARa, and UCP1
involved in b-oxidation were signiﬁcantly upregulated by 1.5-,
4.2-, 3.2-, and 1.9-fold in 1,25(OH)2D-treated cells compared
with the vehicle control (Fig. 4B). Furthermore, 1,25(OH)2D
increased lipolytic enzymes hormone-sensitive lipase (HSL) and
lipoprotein lipase (LPL) mRNA levels by 76.5% and 95.4%,
respectively, in mature adipocytes (P < 0.05). 1,25(OH)2D
responsive gene, CYP24 was signiﬁcantly increased, but leptin,
an obesity-associated adipocytokine secreted by adipose tissue,
was not signiﬁcantly changed by 24 h incubation of 1,25(OH)
2D.y 6 or 7 after differention induction, the cells were incubated with 0 (vehicle), 1, 10, or
an  SEM (n ¼ 6w12/group). *P < 0.05; yP < 0.01 compared with the vehicle control.
Fig. 2. The inhibitory effect of 1,25(OH)2D on lipid accumulation. 3T3-L1 adipocytes were treated with 1,25(OH)2D for 24 h in a dose-dependent manner (0, 1, 10, or
100 nmol/L) on day 6 or 7. Incubated mature 3T3-L1 adipocytes with 1,25(OH)2D was subjected to Oil Red O (ORO) staining and quantitative analysis was conducted (A). The
data are expressed as the mean  SEM (n ¼ 6w9/group). *P < 0.05; yP < 0.01 compared with the vehicle control. Intracellular lipid accumulation was observed by ORO
staining and photographed under light microscopy (magniﬁcation 40), Scale bars ¼ 50 mm (B).
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activity
The effect of 1,25(OH)2Don SIRT1 involved in lipidmetabolism
through the regulation in fat mobilization has never been re-
ported. Therefore, we examined the inﬂuence of 1,25(OH)2D on
gene expression and activity of SIRT1 in 3T3-L1 adipocytes.
1,25(OH)2D-treated adipocytes had a 2-fold increase in SIRT1
mRNA expression compared with vehicle (100% ethanol)-treated
control cells (Fig. 5A). Moreover, 1,25(OH)2D signiﬁcantly
increased SIRT1 activity in a dose-dependentmanner, started at a
dose of 1 nmol/L. The maximum SIRT1 activity was at a concen-
tration of 100 nmol/L by 3.3-fold comparedwith vehicle (Fig. 5B).1,25(OH)2D treatment increases NAD and the NAD-to-NADH
ratio
Upon observing the results showing that 1,25(OH)2D-
increased SIRT1 expression and activity, we investigated whether
1,25(OH)2D regulates adipocyte NAD biology by measuring NAD,
NADH, and the NAD-to-NADH ratio in 3T3-L1 adipocytes. AsFig. 3. The inﬂuence of 1,25(OH)2D on adipocyte lipid utilization. Cell culture su-
pernatant was collected after 24 h of 1,25(OH)2D treatment (0, 1, 10, or 100 nmol/L)
on day 7 and the glycerol content was determined. Lipolysis was stimulated by
adding 10 mmol/L isoproterenol in 2% fatty acid-free albumin to adipocytes pre-
treated for 24 h with 1,25(OH)2D. Lipolysis is presented as the mean glycerol
release/h normalized to the total intracellular protein. The data are expressed as the
mean  SEM (n ¼ 6/group). yP < 0.01 compared with the vehicle control in the
absence of isoproterenol. zP < 0.05; xP < 0.01 compared with the vehicle control in
the present of 10 mmol/L isoproterenol.shown in Figure 6, 100 nmol/L 1,25(OH)2D treatment signiﬁ-
cantly increased the NAD-to-NADH ratio but decreased NADH
levels in differentiated 3T3-L1 cells.Discussion
Associations between vitamin D status and obesity have been
well documented in both epidemiologic and intervention
studies. There is a high prevalence of vitamin D inadequacy in
obese individuals. The present study demonstrates reduced fat
accumulation and increased lipid mobilization with 1,25(OH)2D
treatment in murine mature adipocytes. To the best of our
knowledge, this study describes the ﬁrst time that 1,25(OH)2D
treatment signiﬁcantly increases adipocyte SIRT1 activity and
the NAD-to-NADH ratio. These results suggest that vitamin D
might promote fat mobilization and hence decrease intracellular
fat accumulation and increase lipolysis, concurrently with an
increase of activity in the NAD-SIRT1 pathway.
Adipose tissue is now recognized as one of themost important
tissues in obesity due to its dynamic changes during the pro-
gression of obesity: hyperplasia (an increase in cell number),
hypertrophy (enlarged cell size), and adipocyte-derived peptides
[3–5]. Targeting adipose development during the progression of
obesity has been considered for the prevention and/or treatment
of obesity and its associated metabolic disorders. First, we
examined whether 1,25(OH)2D modulates adipocyte lipid meta-
bolism. Adipocyte lipid accumulationwas signiﬁcantly decreased
in1,25(OH)2D-treated adipocyteswithout intracellular toxicity in
the present study. A published paper showed that 1,25(OH)
2D-induced apoptosis which, in turn, might result in the pre-
vention and treatment of obesity [29]. Treatment of 1,25(OH)2D
(12.5–400 nmol/L) was started at day 0, when differentiationwas
inducedand1,25(OH)2Dwas incubated for1, 3, or 6d.However, in
the current study, mature adipocytes on day 6 or 7 was incubated
with 1,25(OH)2D for 24 h (1–100 nmol/L). Despite this discrep-
ancy, a study to investigate whether 1,25(OH)2D treatment in-
duces apoptosis and its-associated decrease of lipid deposition in
mature adipocyte is warranted. Additionally, our data illustrate
that 1,25(OH)2D treatment increases fatmobilization by reducing
intracellular fat contents and increasing both basal and
isoproterenol-stimulated lipolysis. These results support human
epidemiological and clinical studies demonstrating the negative
association between adiposity/obesity and vitamin D status
[8–10].
Fig. 4. The effects of 1,25(OH)2D on gene expression involved in adipogenesis, fatty acid oxidation, lipolytic enzymes, vitamin D metabolism and obesity-associated adi-
pocytokine. 3T3-L1 adipocytes were incubated with 100 nmol/L 1,25(OH)2D for 24 h on day 6 or 7 after differentiation induction. Gene expression related to adipogenesis (A),
fatty acid oxidation (B), and lipolytic enzymes (C) was analyzed by RT-PCR. CYP24 (D) and leptin (E) mRNA levels were also evaluated. mRNA gene expression was normalized
with respect to the b-actin level. The results are presented as the mean  SEM (n ¼ 9/group). *P < 0.05; yP < 0.01 compared with the vehicle control.
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signiﬁcantly inhibited adipocyte differentiation by suppressing
the expression of adipogenic genes such as CEBPa and PPARg in
murine 3T3-L1 and primary porcine cells [13,14,30]. Consistent
with these studies, results from the present study also demon-
strated that 1,25(OH)2D treatment signiﬁcantly inhibited adi-
pogenic transcription factors, despite the addition of 1,25(OH)2D
in the mature status after differentiation (day 6 or 7) and only for
24 h. The lipogenic mRNA expression related to lipid accumu-
lation was measured. aP2 indicates the extent of fat accumula-
tion in adipose tissue [31]. Fatty acid synthase (FAS) induces de
novo lipogenesis [32]. Additionally, stearoyl-coenzyme desatur-
ase (SCD) converts saturated long-chain Fas (LCFAs) toFig. 5. The effect of 1,25(OH)2D on the mRNA expression and activity of SIRT1. On da
concentrations. The mRNA levels of SIRT1 were determined by reverse transcription po
samples to b-actin. (B) SIRT1 activity was analyzed by a ﬂuorometric SIRT1 activity ass
yP < 0.01 compared with the vehicle control.monounsaturated fatty acids, which are the major components
of triacylglycerol (TG) [33]. In the present study, 1,25(OH)2D
signiﬁcantly decreased these three lipogenic mRNA levels, sug-
gesting the role of 1,25(OH)2D in the decrement of adipocyte fat
storage capacity. Additionally, our results show that the gene
expression involved in fatty acid oxidationwas upregulated by 1,
25(OH)2D treatment. Fatty acid oxidation is regulated by the
CPT1-mediated entry of LCFAs into mitochondria [34] and a
transcription factor, PGC1a. PGC1a promotes lipid catabolism by
regulating mitochondrial biogenesis and metabolism in associ-
ation with its nuclear receptors, PPARa and UCP1, and
gene-encoding respiratory chain proteins involved in thermo-
genesis [35–37]. These data suggest that 1,25(OH)2D-increasedy 6, 3T3-L1 adipocytes were incubated with 1,25(OH)2D for 24 h at the indicated
lymerase chain reaction (RT-PCR) (A). Quantitative RT-PCR was normalized for all
ay kit. The results are expressed as the mean  SEM (n ¼ 6w9/group). *P < 0.05;
Fig. 6. The inﬂuence of 1,25(OH)2D on the levels of NAD (A) and NADH (B) and the NAD-to-NADH ratio (C) in 3T3-L1 adipocytes. 1,25(OH)2D (10 or 100 nmol/L, 24 (h) was
used to treat 3T3-L1 adipocytes on day 6. Cell lysates containing NAD and NADH or NAD-decomposed samples including only NADH were used for the measurement. The
results are expressed as the mean  SEM (n ¼ 6/group). *P < 0.05; yP < 0.01 compared with the vehicle-treated 3T3-L1 adipocytes.
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capacity. In the present study, lipolytic enzymes HSL and LPL
were upregulated by 1,25(OH)2D, which is consistent with the
ﬁndings of a cross-sectional study showing a positive correlation
between vitamin D status and LPL [38], and in vitro studies
demonstrating the increased expression of LPL in 1,25(OH)
2D-treated 3T3-L1 and human adipocytes [16,17,39]. The
reduction of adipogenic gene expression and the increase of
b-oxidation and lipolytic mRNA expression suggest that these
may play a role in the changes of 1,25(OH)2D-induced adipocyte
fat storage and lipolysis. Moreover, vitamin D target gene, CYP24,
is signiﬁcantly induced in the current study, consistent with
dose-responsive increments in 1,25(OH)2D-treated adipocytes
[17,40]. However, further studies to investigate whether 1,
25(OH)2D-induced changes in gene expression is
dose-responsive and how 1,25(OH)2D affects the expression of
genes and/or their enzyme activities are needed. Close associa-
tion between obesity-induced production of leptin and vitamin
D metabolism have been observed in both humans and in vitro
systems [41,42]. However, in the present study, 1,25(OH)2D
treatment did not change leptin gene expression. Therefore,
further study to investigate whether not only 1,25(OH)2D but
also different vitamin D metabolite, such as 25(OH)D affects
production and secretion of leptin in adipocytes needs to be
clariﬁed. Additionally, 1,25(OH)2D-mediated adipocyte adipo-
genesis and adipocyte marker gene regulation are discrepant
according to cell type/origin. In 3T3-L1 cells, 1,25(OH)2D treat-
ment started at day 0 signiﬁcantly inhibits adipogenesis and
intracellular fat accumulation by down-regulating adipocyte
markers such as CEBPa, CEBPb, PPARg, or sterol regulatory
element-binding protein 1 (SREBP1) [13,14]. In contrast, 1,25(OH)
2D-treated human subcutaneous preadipocytes demonstrated
increased adipogenesis determined by increased gene expres-
sion of PPARg and TG accumulation. There is no distinct change
in CEBPa and CEBPb levels [17]. Therefore, it is necessary to
investigate the inﬂuence of 1,25(OH)2D on fat utilization in
human adipocytes.
Accumulating evidence demonstrates that SIRT1 activation
plays an important role in metabolic functions by increasing the
b-oxidation of free fatty acids and mitochondrial biogenesis in a
NAD-dependent manner [18,21,22,43]. The major metabolic
roles of NAD and NADH are associated with oxidativemetabolism and energy homeostasis, which have been linked to
protection against obesity [44,45]. In this study, we revealed that
1,25(OH)2D increased intracellular NAD levels and the NAD/-
NADH ratio in 3T3-L1 adipocytes. We also found that 1,25(OH)2D
treatment increased both SIRT1 expression and activity. A
NAD-dependent deacetlyase, SIRT1, regulates adipose energy
homeostasis and metabolism, which could be a potential thera-
peutic strategy to protect against obesity and obesity-associated
metabolic disorders [46,47]. Additionally, SIRT1 inhibits pre-
adipocyte differentiation and increases the mobilization of free
fatty acids from adipose tissues [23]. Furthermore, there is
accumulating evidence showing an inverse association between
SIRT1 levels and adipose tissue mass and inﬂammation [24,25,
48]. Moreover, targeting SIRT1 activation by resveratrol supple-
mentation shows the favorable effect on body composition in
humans [26]. A recent research proposes SIRT1 activation is
closely related to the activation of a steroid hormone receptor,
vitamin D receptor (VDR), which mediates 1,25(OH)2D-induced
genomic changes [49]. SIRT1 activator, resveratrol, signiﬁcantly
stimulates 1,25(OH)2D binding to VDR, the recruitment of its
co-receptor, retinoid X receptor (RXR), and SIRT1 activation in
human colorectal adenocarcinoma cells (Caco-2, HCT116),
human embryonic kidney cells (HEK293), and mouse myoblast
cells (C2 C12) cells [50]. Thus, because NAD and SIRT1 protect
against adipose tissue mass and the derangement of metabolic
functions that are known to related to obesity, we speculate that
1,25(OH)2D-induced adipocyte fat storage and lipolysis might be
related to a NAD-sirtulin pathway. Further research is necessary
to delineate whether 1,25(OH)2D-elevated NAD levels lead to
changes in PGC-1a deacetylation, mitochondria biogenesis,
oxidative respiration, fatty acid oxidation, and energy homeo-
stasis in a SIRT1-dependent manner and/or in a VDR-mediated
manner in adipocytes and in vivo animal studies.
Conclusion
The present data demonstrated that the favorable effects of
vitamin D,1,25(OH)2D on adipocytemetabolism and function are
associated with decreased adipocyte fat storage and increased
lipolysis. 1,25(OH)2D treatment modulates adipogenic, fatty acid
oxidation, or lipolytic related gene expression and increases the
NAD-sirutlin pathway activity in 3T3-L1 adipocytes. Findings
E. Chang, Y. Kim / Nutrition 32 (2016) 702–708708from this study suggest that increasing vitamin D status might be
an effective strategy for preventing obesity. Further research is
warranted to explore the mechanisms of how vitamin D directly
affects sirtuin-mediated metabolic regulation in adipocyte
metabolism and obesity.
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